We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Reasons to Add Merit Medical (MMSI) to Your Portfolio Now
Read MoreHide Full Article
Merit Medical Systems, Inc. (MMSI - Free Report) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by solid third-quarter 2023 performance and the company’s continued spend on research and development (R&D), is expected to contribute further. However, headwinds due to higher consolidation in the healthcare industry and stiff competition persist.
Over the past year, this currently Zacks Rank #2 (Buy) stock has risen 15% compared with the industry’s 9.1% growth. The S&P 500 grew 20.8% during the same time frame.
The renowned medical device provider has a market capitalization of $4.56 billion. The company projects 11.5% growth for the next five years and expects to maintain its strong performance going forward. It delivered an average earnings surprise of 14.41% for the past four quarters.
Image Source: Zacks Investment Research
Let’s delve deeper.
Strong Product Portfolio: Merit Medical has continued to gain significant momentum on the back of new products. The company is upbeat about the product pipeline, including radio and electrophysiology products, raising investors’ optimism. In October, MMSI announced the expansion of its Maestro Microcatheter product line to include a new longer length for radial embolization procedures.
In September, Merit Medical announced the U.S. commercial release of its Aspira Bottle.
Continued Spend on R&D: Merit Medical’s R&D operations have been central to its historical growth and are believed to be critical to its continued development. In recent years, the company’s focus on innovation has led to the introduction of several new products, improvements to its existing products, and expansion of its product lines, as well as enhancements and new equipment in its R&D facilities. This raises our optimism.
Strong Q3 Results: Merit Medical’s robust third-quarter 2023 results buoy optimism. The company witnessed a year-over-year uptick in the top and bottom lines. The company also saw revenue growth in both its segments and across all the product categories within its Cardiovascular unit. Robust performances in the United States and outside were also registered. The expansion of both margins bodes well for the stock. Per preliminary results announced earlier this month, MMSI is expected to generate revenues in the band of $322-$326 million during the fourth quarter.
Downsides
Higher Consolidation in the Healthcare Industry: Healthcare costs have risen significantly over the past decade. Thus, to provide healthcare solutions at a cheaper rate and eradicate competition, large-cap MedTech behemoths have started consolidating with mid-cap and small-cap companies. This enables the availability of healthcare products at cheap prices in the market. Per management, such trends compel Merit Medical’s customers to ask for price concessions on its products, which acts against the ongoing business strategies. This may also exert a solid downward pressure on the prices of Merit Medical’s products and hurt the customer base.
Stiff Competition: Merit Medical operates in highly competitive markets, where it faces competition from many companies with greater resources. Such resources and market presence may enable the competitors to market competing products more efficiently or at reduced prices to gain market share.
Estimate Trend
Merit Medical is witnessing a positive estimate revision trend for 2023. In the past 60 days, the Zacks Consensus Estimate for earnings has moved up from $2.96 per share to $2.97.
The Zacks Consensus Estimate for the company’s fourth-quarter 2023 revenues is pegged at $317 million, indicating an 8.1% increase from the year-ago quarter’s reported number.
Some other top-ranked stocks in the broader medical space are DaVita Inc. (DVA - Free Report) , Cardinal Health (CAH - Free Report) and Integer Holdings Corporation (ITGR - Free Report) .
DaVita, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 17.3%. DVA’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 36.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DaVita’s shares have risen 30.6% compared with the industry’s 6.4% growth in the past year.
Cardinal Health, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 15.3%. CAH’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 15.67%.
Cardinal Health’s shares have risen 39.5% compared with the industry’s 9.1% growth in the past year.
Integer Holdings, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 15.8%. ITGR’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 11.9%.
Integer Holdings’ shares have risen 39.2% against the industry’s 0.7% decline in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Reasons to Add Merit Medical (MMSI) to Your Portfolio Now
Merit Medical Systems, Inc. (MMSI - Free Report) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by solid third-quarter 2023 performance and the company’s continued spend on research and development (R&D), is expected to contribute further. However, headwinds due to higher consolidation in the healthcare industry and stiff competition persist.
Over the past year, this currently Zacks Rank #2 (Buy) stock has risen 15% compared with the industry’s 9.1% growth. The S&P 500 grew 20.8% during the same time frame.
The renowned medical device provider has a market capitalization of $4.56 billion. The company projects 11.5% growth for the next five years and expects to maintain its strong performance going forward. It delivered an average earnings surprise of 14.41% for the past four quarters.
Image Source: Zacks Investment Research
Let’s delve deeper.
Strong Product Portfolio: Merit Medical has continued to gain significant momentum on the back of new products. The company is upbeat about the product pipeline, including radio and electrophysiology products, raising investors’ optimism. In October, MMSI announced the expansion of its Maestro Microcatheter product line to include a new longer length for radial embolization procedures.
In September, Merit Medical announced the U.S. commercial release of its Aspira Bottle.
Continued Spend on R&D: Merit Medical’s R&D operations have been central to its historical growth and are believed to be critical to its continued development. In recent years, the company’s focus on innovation has led to the introduction of several new products, improvements to its existing products, and expansion of its product lines, as well as enhancements and new equipment in its R&D facilities. This raises our optimism.
Strong Q3 Results: Merit Medical’s robust third-quarter 2023 results buoy optimism. The company witnessed a year-over-year uptick in the top and bottom lines. The company also saw revenue growth in both its segments and across all the product categories within its Cardiovascular unit. Robust performances in the United States and outside were also registered. The expansion of both margins bodes well for the stock. Per preliminary results announced earlier this month, MMSI is expected to generate revenues in the band of $322-$326 million during the fourth quarter.
Downsides
Higher Consolidation in the Healthcare Industry: Healthcare costs have risen significantly over the past decade. Thus, to provide healthcare solutions at a cheaper rate and eradicate competition, large-cap MedTech behemoths have started consolidating with mid-cap and small-cap companies. This enables the availability of healthcare products at cheap prices in the market. Per management, such trends compel Merit Medical’s customers to ask for price concessions on its products, which acts against the ongoing business strategies. This may also exert a solid downward pressure on the prices of Merit Medical’s products and hurt the customer base.
Stiff Competition: Merit Medical operates in highly competitive markets, where it faces competition from many companies with greater resources. Such resources and market presence may enable the competitors to market competing products more efficiently or at reduced prices to gain market share.
Estimate Trend
Merit Medical is witnessing a positive estimate revision trend for 2023. In the past 60 days, the Zacks Consensus Estimate for earnings has moved up from $2.96 per share to $2.97.
The Zacks Consensus Estimate for the company’s fourth-quarter 2023 revenues is pegged at $317 million, indicating an 8.1% increase from the year-ago quarter’s reported number.
Merit Medical Systems, Inc. Price
Merit Medical Systems, Inc. price | Merit Medical Systems, Inc. Quote
Other Stocks to Consider
Some other top-ranked stocks in the broader medical space are DaVita Inc. (DVA - Free Report) , Cardinal Health (CAH - Free Report) and Integer Holdings Corporation (ITGR - Free Report) .
DaVita, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 17.3%. DVA’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 36.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DaVita’s shares have risen 30.6% compared with the industry’s 6.4% growth in the past year.
Cardinal Health, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 15.3%. CAH’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 15.67%.
Cardinal Health’s shares have risen 39.5% compared with the industry’s 9.1% growth in the past year.
Integer Holdings, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 15.8%. ITGR’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 11.9%.
Integer Holdings’ shares have risen 39.2% against the industry’s 0.7% decline in the past year.